FIELD: chemistry.SUBSTANCE: invention refers to the crystalline form of the formula (I) compound, wherein the crystalline form is form B, form C, form H or form I. Crystalline form B has the X-ray powder diffraction (XRPD) model, which includes peaks that are expressed in degrees 2θ at 6.68°±0.2°, 13.39°±0.2°, 19.65°±0.2°, 20.26°±0.2°, 22.45°±0.2°, 24.80°±0.2°, 25.01°±0.2°, 26.19°±0.2°, 26.61°±0.2° and 28.79°±0.2°. Crystalline form C has the X-ray powder diffraction (XRPD) model, which includes peaks that are expressed in degrees 2θ at 5.39°±0.2°； 13.25°±0.2°； 16.00°±0.2°； 17.27°±0.2°； 21.33°±0.2°； 21.92°±0.2°； 22.53°±0.2°； 23.47°±0.2°； 26.56°±0.2°； 26.87°±0.2°； 29.41°±0.2° and 32.22°±0.2°. Crystalline form of H has the X-ray powder diffraction (XRPD) model, which includes peaks that are expressed in degrees 2θ at 7.58°±0.2°； 10.29°±0.2°； 12.00°±0.2°； 19.07°±0.2°； 19.93°±0.2°； 20.78°±0.2°； 21.33°±0.2°； 21.48°±0.2°； 24.76°±0.2°； 25.59°±0.2°； 25.82°±0.2°； 26.01°±0.2° and 26.58°±0.2°. Crystalline form is Form I, has a powder X-ray diffraction (XRPD) model including peaks expressed in degrees 2θ at 9.41°±0.2°； 17.59°±0.2°； 21.37°±0.2°； 21.72°±0.2°； 22.15°±0.2°； 22.50°±0.2°； 23.90°±0.2°； 24.59°±0.2°； 24.99°±0.2°； 26.32°±0.2°； 27.09°±0.2°； 29.68°±0.2° and 30.53°±0.2°.EFFECT: crystalline forms of the mesylate salt of 6-[R,S]-ethyl-6-(2-bromo-4-fluorophenyl)-4-(morpholinomethyl)-2-(thiazol-2-yl)-1,6-dihydropyrimidin-5-carboxylate, which are characterized by excellent solubility, stability.15 cl, 12 dwg, 3 tbl, 9 exИзобретение относится к кристаллической форме соединения формулы (I), где кристаллическая форма является формой В, формой С, формой Н или формой I. Кристаллическая форма В имеет модель порошковой рентгеновской дифракции (XRPD), включающей пики, выраженные в градусах 2θ при 6,68°±0,2°, 13,39°±0,2°, 19,65°±0,2°, 20,26°±0,2°, 22,45°±0,2°, 24,80°±0,2°, 25,01°±0,2°, 26,19°±0,2°, 26,61°±0.2° и 28,79°±0,2°. Кристаллическая форма С имеет модель порошковой рентгеновской д
